Despite ‘Almost Nonexistent’ Cough/Cold Season, Perrigo's 2020 Consumer Health Sales Grow 6%

 
• By Malcolm Spicer

Perrigo is latest consumer health firm to note substantially slower flu rates slammed OTC drug sales during 2020 fourth quarter. Its total cough/cold product sales for the year were off $63m on decreases of $34m in the Americas and $29m in its international markets.

Perrigo's total cough/cold products sales for the year were off $63m as reports of cases of flu dropped across its markets, including among adults in the US. • Source: Perrigo 2020 Full-Year/Q4 Earnings Presentation, 1 March, 2021

More from Rx-to-OTC Switch

More from Health